コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 domain Abs have reinvigorated the concept of passive immunization.
2 to a more potent reagent for gene therapy or passive immunization.
3 protected mice from a lethal VV challenge by passive immunization.
4 ization, HSV-1 shedding, and latency through passive immunization.
5 T-helper cell subset 1 response and enables passive immunization.
6 mmunomodulatory effects as well as providing passive immunization.
7 antibodies for virus following active versus passive immunization.
8 transplantation can be reduced by aggressive passive immunization.
9 cued spatial reference memory deficits after passive immunization.
10 IgG-FcgammaR interactions during active and passive immunization.
11 otected against systemic GAS challenge after passive immunization.
12 apsule is a potential therapeutic target via passive immunization.
13 prevention of viral acquisition by active or passive immunization.
14 uction before initiating a 12 week course of passive immunization.
15 human immunodeficiency virus (HIV) has made passive immunization a potential strategy for the preven
19 rides, an iron scavenging protein, isdB, and passive immunization against clumping factor A and lipot
23 utralizing antibodies that could be used for passive immunization against H5N1 virus or as guides for
25 n-sensitive P23 epitopes may have utility in passive immunization against murine C. parvum infection.
29 Ab has an important potential in therapeutic passive immunization and could help HIV-1 infected patie
30 he importance of the antibody format in oral passive immunization and encourage future expression of
31 such infection that may be prevented by oral passive immunization and might avert recurrent economic
32 app = 200 nM) was tested in a mouse model of passive immunization and subsequent mole-equivalent chal
33 uorescence assays, growth inhibition assays, passive immunizations, and active immunizations indicate
35 fic antibodies, acquired by either active or passive immunization, are sufficient to protect against
36 We demonstrate that HCV can be blocked by passive immunization, as well as showing that a recombin
38 thermore, when MIP-2 was depleted in vivo by passive immunization, bleomycin-induced pulmonary fibros
40 Here we show that elements of active and passive immunization can be combined to create an effect
41 -CelTOS responses elicited by vaccination or passive immunization can inhibit sporozoite and ookinete
43 ed by active immunization or administered by passive immunization confer protection against S. aureus
44 us and vaccine-heterologous strains, whereas passive immunization confers only vaccine-homologous pro
48 mited the study's ability to address whether passive immunization diminishes perinatal transmission.
50 serum is sufficient to confer protection, a passive immunization experiment using pooled nHgbA antis
52 virus (ZEBOV) have been successfully used in passive immunization experiments in rodent models, but h
54 al passive immunity in fish and fish-to-fish passive immunization experiments supports the concept of
56 isms underlying host resistance, a series of passive immunization experiments were carried out using
58 om a lethal intranasal challenge with WU2 in passive-immunization experiments in which 10 mug of the
59 only a subset of G(C) MAbs protected mice in passive-immunization experiments, while some nonneutrali
63 soluble Abeta and tau levels after active or passive immunization in advanced aged 3xTg-AD mice that
64 omer-specific monoclonal antibody (TOMA) for passive immunization in mice expressing mutant human tau
67 l likely shape efforts to develop active and passive immunization interventions in response to the re
71 ocked TIGR4 adhesion in vitro and, following passive immunization, it protected mice against challeng
72 c antibodies in both the sera and lungs, and passive immunization led to the reduction of B. bronchis
73 a longer period of active immunotherapy, or passive immunization, may be required to provide suffici
74 enal disease is prevented in both active and passive immunization models by antigen-specific IgG1; ot
80 o the control normal mouse immunoglobulin G, passive immunization of BALB/c mice with MAb MoPn-23 res
84 n of rheumatoid arthritis (RA) by active and passive immunization of mice results in the development
87 t, when performed during progression of HUS, passive immunization of mice with anti-Stx2 antibody pre
96 ight be paired with antibiotic treatment for passive immunization of patients suffering from P. aerug
101 This report examines the effects of chronic, passive immunization on VAbeta and microhemorrhage in PD
103 ns of ETA, may have therapeutic potential in passive immunization or topical treatment of burn patien
104 from nasopharyngeal infection; however, only passive immunization, or vaccination with inactive SpeA,
106 red to controls (5.64; P = 0.0480), and both passive immunizations (PLY = 31.34% loss of retinal func
107 This compensating effect was blocked by passive immunization pretreatment with the monoclonal Ig
109 thers have demonstrated that both active and passive immunizations reduce Tau pathology and prevent c
112 epithelial neutrophil activating protein by passive immunization significantly attenuated neutrophil
117 efore increase the potency and durability of passive immunization strategies to prevent HIV-1 infecti
118 s to date have focused on the development of passive immunization strategies to prevent or treat diss
122 e of antibody preparations as a prophylactic passive immunization strategy in large populations.
123 c principles and scientific premises for the passive immunization strategy, including existing and em
133 ccine design, our data have implications for passive-immunization studies in countries where clade C
137 clinical studies demonstrate that active and passive immunizations targeting alpha-syn partially amel
138 ct against S. aureus infection of active and passive immunization that targeted 3 proteins involved i
141 ely developed is immunotherapy-specifically, passive immunization through administration of exogenous
144 in the presence of maternal immunity or upon passive immunization to rabies virus with the pSG5rab.gp
146 n the absence of an effective HIV-1 vaccine, passive immunization using broadly neutralizing Abs or A
147 of FcRn-transported IgG was demonstrated by passive immunization using herpes simplex virus-2 (HSV-2
150 tly, for the first time, we demonstrate that passive immunization using the antibody NT4X is therapeu
152 r, virus isolated from 1 mouse 3 weeks after passive immunization with 13.2 mg/kg antibody proved res
154 e protected against lethality by intravenous passive immunization with a CPB antibody prior to intrag
160 vent or treat AD, we compared the effects of passive immunization with an anti-Abeta42 mAb, an anti-A
161 laboratory has previously demonstrated that passive immunization with an anti-tau antibody, HJ8.5, d
164 e protected against lethality by intravenous passive immunization with an epsilon toxin antibody prio
165 ion with the amyloid beta (Abeta) protein or passive immunization with anti-Abeta antibodies has bene
166 protein transgenic mice have suggested that passive immunization with anti-Abeta antibodies may clea
178 he disease are currently available, although passive immunization with C. parvum-specific antibodies
179 ly, studies in these same mice indicate that passive immunization with certain anti-Abeta antibodies
186 on and survival) was completely abrogated by passive immunization with high-titer human anti-MV antib
189 We and others have previously shown that passive immunization with human nMAbs protected adult or
190 AIDS, the potential of pre- and postexposure passive immunization with hyperimmune serum to prevent o
191 llenging with the immunizing antigen, and by passive immunization with IgG or IgE anti-2,4,6-trinitro
194 roups of animals were given one prechallenge passive immunization with immune rabbit serum (IRS), M13
195 uire Ag in sensitized Ig-deficient mice, and passive immunization with immune serum or Ag-specific Ig
203 (FnBPA) and fibronectin-binding protein B or passive immunization with monoclonal antibodies against
204 e to bind to the surface of M. tuberculosis, passive immunization with monoclonal antibodies directed
207 tion with recombinant PR (rPR) molecules and passive immunization with monoclonal antibodies reactive
212 pithelial neutrophil activating protein; (2) passive immunization with neutralizing antibodies to TNF
213 immunization with nontoxigenic Hla(H35L) or passive immunization with neutralizing monoclonal antibo
214 udy have implications for the improvement of passive immunization with polyclonal or monoclonal antib
216 al challenge with P. yoelii sporozoites than passive immunization with purified IgG from rabbits immu
218 Active immunization with recombinant SasX or passive immunization with rabbit polyclonal anti-SasX Ig
219 ne mice challenged by transplantation and by passive immunization with sera from mice infected with e
220 amyloid peptide (Alphabeta) with vaccines or passive immunization with systemic monoclonal anti-Abeta
221 he aim of this study is to determine whether passive immunization with the 23-valent pneumococcal pol
223 This study reports the effect of active or passive immunization with the conjugates or their antise
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。